Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mark Webster is active.

Publication


Featured researches published by Mark Webster.


American Journal of Cardiology | 1998

Results of percutaneous coronary angioplasty in patients < 40 years of age

C. Ellis; John K. French; Harvey D. White; John Ormiston; R. M. L. Whitlock; Mark Webster

This study examined factors influencing the outcome of percutaneous transluminal coronary angioplasty (PTCA) in patients <40 years of age. We followed 86 patients (mean age 37 years) treated from 1982 to 1994. The primary procedural success was 90%. At follow-up of 83 patients (97%) at a mean of 48 +/- 33 months (range 5 to 147), there had been 3 late deaths. Actuarial survival at 5 and 10 years was 95% and 91%, respectively. At review only 5% of patients had class III angina and no patient had class IV angina. Repeat revascularization (PTCA alone in 21 [25%], surgery in 8 [10%], or both in 10 [12%] patients) was performed for restenosis in 29 patients (35%) and for disease progression at other sites in 10 patients (12%). On multivariate analysis, a history of diabetes mellitus (p <0.02) was the only factor associated with death or a subsequent cardiovascular event (myocardial infarction, stroke, or hospital admission with unstable angina). At follow-up, 20 patients (24%) still smoked, 64 (77%) had a total cholesterol level > or = 200 mg/dl, 20 (24%) had a body mass index > or = 30, and 15 (18%) were not taking aspirin. In conclusion, PTCA in adults <40 years of age has excellent early results with a low morbidity and mortality. The medium-term prognosis and control of symptoms was good, although by 5 years, further revascularization was required in almost half of the patients.


Open Heart | 2017

Long and short of optimal stent design

Timothy Watson; Mark Webster; John A. Ormiston; Peter Ruygrok; James T. Stewart

The ideal stent must fulfil a broad range of technical requirements. Stents must be securely crimped onto the delivery balloon and, in this form, must have a low profile and be sufficiently flexible to facilitate deliverability to the lesion site without distortion or displacement. Following expansion, stents must exert sufficient radial force on the vessel wall to overcome lesion resistance and elastic recoil. To achieve an optimal lumen diameter, the lesion must be uniformly and adequately scaffolded, with minimal tissue prolapse between struts but without compromising side-branch access. Furthermore, the deployed stent must conform to the vessel curvature to minimise vessel distortion, particularly at the stent edges. Radio-opacity is also important to guide safe positioning, adequate deployment and postdilataion and to permit assessment of optimal stent expansion. Equally though, the stent lumen must also be sufficiently visible to allow radiographic assessment of flow dynamics and restenosis. Efforts to optimise one characteristic of stent design may have detrimental effects on another. Thus, currently available stents all reflect a compromise between competing desirable features and have subtle differences in their performance characteristics. Striving to achieve stents with optimal deliverability, conformability and radial strength led to a reduction in longitudinal strength. The importance of this parameter was highlighted by complications occurring in the real-world setting where percutaneous coronary intervention is often undertaken in challenging anatomy. This review focuses on aspects of stent design relevant to longitudinal strength.


Bifurcation Stenting | 2012

Percutaneous Coronary Intervention for Bifurcation Lesions: Bench Testing and the Real World

John A. Ormiston; Mark Webster; Bruce Webber


Archive | 2010

Methods for the assessment of drug response

Patrick Gladding; Arzu Gunes; Marja-Liisa Dahl; Mark Webster


Archive | 2009

Stent delivery at a bifurcation, systems and methods

Mark Webster; John A. Ormiston


Archive | 2011

Bench Insights Into a Clinical Problem

John A. Ormiston; Bruce Webber; Mark Webster


/data/revues/14439506/v21i3/S1443950611013229/ | 2012

Clinical Characteristics and Outcome of Apical Ballooning Syndrome in Auckland, New Zealand

Jen-Li Looi; Chi-Wing Wong; Ali Khan; Mark Webster; Andrew Kerr


/data/revues/14439506/v18sS3/S144395060900482X/ | 2011

Rapid Pharmacogenetic Testing for Clopidogrel Using the INFINITI Analyser: A Dose Escalation Study

Patrick Gladding; Mark Webster; John A. Ormiston; James R. Stewart; Peter Ruygrok; Ken Fu; Ruth Baak


/data/revues/14439506/v12i2/S1443950603901624/ | 2011

Spontaneous coronary artery dissection

Rob Butler; Mark Webster; Gershan Davies; Andrew Kerr; Guy Armstrong; Nigel M. Bass; John A. Ormiston; Charles Peebles


/data/revues/00028703/v155i4/S0002870308000720/ | 2011

Antiplatelet drug nonresponsiveness

Patrick Gladding; Mark Webster; John A. Ormiston; Sarah Olsen; Harvey D. White

Collaboration


Dive into the Mark Webster's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Harvey D. White

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge